| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3876 | 2015 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1450 | 2016 |
| Genomic correlates of clinical outcome in advanced prostate cancer W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ... Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019 | 1147 | 2019 |
| Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy JE Rosenberg, PH O’Donnell, AV Balar, BA McGregor, EI Heath, EY Yu, ... Journal of Clinical Oncology 37 (29), 2592-2600, 2019 | 565 | 2019 |
| Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer YM Wu, M Cieślik, RJ Lonigro, P Vats, MA Reimers, X Cao, Y Ning, ... Cell 173 (7), 1770-1782. e14, 2018 | 537 | 2018 |
| Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer LM Hamel, LA Penner, TL Albrecht, E Heath, CK Gwede, S Eggly Cancer control 23 (4), 327-337, 2016 | 436 | 2016 |
| The current state of molecular testing in the treatment of patients with solid tumors, 2019 WS El‐Deiry, RM Goldberg, HJ Lenz, AF Shields, GT Gibney, AR Tan, ... CA: a cancer journal for clinicians 69 (4), 305-343, 2019 | 265 | 2019 |
| Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM D Kong, E Heath, W Chen, ML Cher, I Powell, L Heilbrun, Y Li, S Ali, ... PloS one 7 (3), e33729, 2012 | 250 | 2012 |
| EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma J Rosenberg, SS Sridhar, J Zhang, D Smith, D Ruether, TW Flaig, ... Journal of Clinical Oncology 38 (10), 1041-1049, 2020 | 236 | 2020 |
| A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 JP Eder, GI Shapiro, LJ Appleman, AX Zhu, D Miles, H Keer, B Cancilla, ... Clinical Cancer Research 16 (13), 3507-3516, 2010 | 235 | 2010 |
| A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer EI Heath, DW Hillman, U Vaishampayan, S Sheng, F Sarkar, F Harper, ... Clinical Cancer Research 14 (23), 7940-7946, 2008 | 217 | 2008 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 215 | 2022 |
| Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration‐resistant prostate cancer ES Antonarakis, EI Heath, DC Smith, D Rathkopf, AL Blackford, DC Danila, ... The oncologist 18 (2), 163-173, 2013 | 214 | 2013 |
| Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial EI Heath, MI Canto, S Piantadosi, E Montgomery, WM Weinstein, ... Journal of the National Cancer Institute 99 (7), 545-557, 2007 | 209 | 2007 |
| Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial YY Evan, DP Petrylak, PH O'Donnell, JL Lee, MS van der Heijden, ... The Lancet Oncology 22 (6), 872-882, 2021 | 199 | 2021 |
| Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update J Chin, RB Rumble, M Kollmeier, E Heath, J Efstathiou, T Dorff, B Berman, ... Journal of Clinical Oncology 35 (15), 1737-1743, 2017 | 182 | 2017 |
| Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus EI Heath, BA Burtness, RF Heitmiller, R Salem, L Kleinberg, JPS Knisely, ... Journal of clinical oncology 18 (4), 868-868, 2000 | 174 | 2000 |
| Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial PG Corn, EI Heath, A Zurita, N Ramesh, L Xiao, E Sei, E Li-Ning-Tapia, ... The lancet oncology 20 (10), 1432-1443, 2019 | 173 | 2019 |
| Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative … MK Gibson, SC Abraham, TT Wu, B Burtness, RF Heitmiller, E Heath, ... Clinical Cancer Research 9 (17), 6461-6468, 2003 | 160 | 2003 |
| A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 NB Haas, X Lin, J Manola, M Pins, G Liu, D McDermott, D Nanus, E Heath, ... Medical Oncology 29, 761-767, 2012 | 150 | 2012 |
